Vericel (VCEL) Free Cash Flow (2010 - 2026)
Vericel (VCEL) posted Free Cash Flow of $14.5 million for Q2 2026, down 3.08% sequentially from $14.9 million in Q1 2026, and up 17755.56% YoY from N/an in Q2 2025.
Vericel (VCEL) Free Cash Flow (2010 - 2026) Analysis & Trends
Vericel has reported Free Cash Flow for 17 years, with the latest figure at $14.5 million in Q2 2026.
- Quarterly Free Cash Flow rose 17755.56% year-over-year to $14.5 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $61.7 million (up 842.85% YoY) and the FY2025 annual result came in at $24.7 million, up 525.88% from the prior year.
- Free Cash Flow fell to $14.5 million in Q2 2026 per VCEL's latest filing, from $14.9 million in the prior quarter.
- Over five years, Free Cash Flow peaked at $19.5 million in Q3 2025 and troughed at -$9.2 million in Q3 2024.
- A 5-year average of $4.1 million and a median of $2.5 million in 2022 frame the typical range for Free Cash Flow.
- The sharpest annual moves came in 2024 and 2026: Free Cash Flow plunged 1637.5% in 2024, then soared 17755.56% in 2026.
- Over 5 years, Free Cash Flow stood at $5.6 million in 2022, then tumbled by 59.96% to $2.3 million in 2023, then jumped by 275.61% to $8.5 million in 2024, then surged by 51.71% to $12.8 million in 2025, then rose by 12.75% to $14.5 million in 2026.
- According to Business Quant data, Free Cash Flow over the past three periods registered $14.5 million, $14.9 million, and $12.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -389.61 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 437.80 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 477.44 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 292.04 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Vericel | 2.26 Bn | 2.10 Bn | 56.40 Mn | 14.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 14.46 Mn |
| Jun 30, 2026 | 14.46 Mn |
| Mar 31, 2026 | 15.13 Mn |
| Mar 31, 2026 | 15.13 Mn |
| Dec 31, 2025 | -11.02 Mn |
| Dec 31, 2025 | -11.02 Mn |
| Sep 30, 2025 | 43.30 Mn |
| Sep 30, 2025 | 43.30 Mn |
| Jun 30, 2025 | 81,000.00 |
| Jun 30, 2025 | 81,000.00 |
| Mar 31, 2025 | -7.61 Mn |
| Mar 31, 2025 | -7.61 Mn |
| Dec 31, 2024 | 60.53 Mn |
| Dec 31, 2024 | 60.53 Mn |
| Sep 30, 2024 | -9.23 Mn |
| Sep 30, 2024 | -9.23 Mn |
| Jun 30, 2024 | -128,000.00 |
| Jun 30, 2024 | -128,000.00 |
| Mar 31, 2024 | -4.91 Mn |
| Mar 31, 2024 | -4.91 Mn |